1: Lansiaux A, Bailly C. Le NB-506 [NB 506]. Bull Cancer. 1999 Mar;86(3):255-8. French. PMID: 10210758.
2: Kanzawa F, Nishio K, Kubota N, Saijo N. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res. 1995 Jul 1;55(13):2806-13. PMID: 7796407.
3: Ren J, Bailly C, Chaires JB. NB-506, an indolocarbazole topoisomerase I inhibitor, binds preferentially to triplex DNA. FEBS Lett. 2000 Mar 31;470(3):355-9. doi: 10.1016/s0014-5793(00)01335-1. PMID: 10745096.
4: Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, Pommier Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res. 2001 Jan 15;61(2):504-8. PMID: 11212241.
5: Facompre M, Goossens JF, Bailly C. Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1. Biochem Pharmacol. 2001 Feb 1;61(3):299-310. doi: 10.1016/s0006-2952(00)00553-0. PMID: 11172734.
6: Vanhoefer U, Voigt W, Hilger RA, Yin MB, Harstrick A, Seeber S, Rustum YM. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Oncol Res. 1997;9(9):485-94. PMID: 9495454.
7: Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M, Saijo N. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 1996 Feb 15;56(4):789-93. PMID: 8631015.
8: Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, Nishimura S. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. 2001 Apr 1;61(7):2827-32. PMID: 11306452.
9: Pilch B, Allemand E, Facompré M, Bailly C, Riou JF, Soret J, Tazi J. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res. 2001 Sep 15;61(18):6876-84. PMID: 11559564.
10: Bailly C, Qu X, Chaires JB, Colson P, Houssier C, Ohkubo M, Nishimura S, Yoshinari T. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. J Med Chem. 1999 Jul 29;42(15):2927-35. doi: 10.1021/jm990108t. PMID: 10425102.